B
BVF Partners L.P.
+ HältNCEL
+8.72%
3-Monats-Rendite
$2.724
-0.156 (-5.73%)Zum Schluss
Loading chart…
- Hoch
- 2.800
- Eröffnung
- 2.800
- Volumengewichteter Durchschnittskurs
- 2.72
- Volumen
- 11.24K
- Marktkap.
- —
- Tief
- 2.645
- Umsatz
- 30.61K
- EV/EBITDA, TTM
- 0.00
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
KI-Analyse of NewcelX AG (NCEL)
KaufenNewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
Bewertungskennzahlen
Das aktuelle erwartete KGV von NewcelX AG (NCEL) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 0.00.
Whales, die NCEL halten
Event-Zeitleiste
News
8.507-31NewsfilterNewcelX Secures Private Placement to Advance Diabetes Therapy
- 5.007-08Newsfilter
NewcelX Appoints Diabetes Research Authority Dr. Camillo Ricordi to Advisory Board
- 8.507-08Newsfilter
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- 8.507-01Newsfilter
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- 3.506-15Newsfilter
NewcelX Publishes AstroRx® Study Results
NCEL FAQ – beantwortet von Alphio AI
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ. It operates in the Healthcare sector.
NewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.